stockrow
Monday 9 November 2026
Export APMD’s income statement to Excel — free account
Apnimed, Inc.
APMDApnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024.
15.10
0.94
+6.64%
Follow APMD
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 8 | 38 | 117 | +380.1% | 91 | 22 | 145 | +55.5% | |
| Gross margin, % | — | — | — | — | — | — | — | — | 57.95 | 82.60 | 94.53 | +24.6 pt | ||||||
| EBT | — | — | — | — | — | — | — | — | (109) | (58) | 164 | (46.5%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | (1,354.84) | (150.91) | 140.16 | +1,203.9 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (111) | (128) | 96 | +15.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 1.69 | 8.08 | 24.42 | +378.2% | |||||
| Earnings | — | — | — | — | — | — | — | — | (23.46) | (26.91) | 19.73 | +14.7% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (23.23) | (16.34) | (17.46) | (29.7%) | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (23.25) | (16.34) | (17.46) | (29.7%) | ||||||
| Book value | — | — | — | — | — | — | — | — | (52.41) | (78.27) | (36.73) | +49.3% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 5 | 5 | 5 | +0.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 1.27 | 1.27 | 0.77 | 1.3 | |||||
| P/S | — | — | — | — | — | — | — | — | 1.02 | 1.02 | 0.62 | 1.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.23 | 0.23 | (0.18) | 0.2 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.32) | (0.32) | 0.25 | (0.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (110) | (78) | (84) | (29.4%) | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (110) | (78) | (84) | (29.4%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 31 | (66) | 149 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | — | (68) | (1) | (93) | (98.2%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (249) | (373) | (176) | +49.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (140.79) | 0.00 | (140.8) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 41.26 | 0.00 | +41.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 65 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.59 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026
Apnimed, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OBX Obsidian Therapeutics, Inc | $856.5M | — | — | — | n/m | — | — | 0.00% | Compare |
| NVCT Nuvectis Pharma, Inc. | $719.1M | — (loss-making) | — | — | n/m | −462.48% (below 0%: shrinking) | — | 0.00% | Compare |
| AVBP ArriVent BioPharma, Inc. | $672.6M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| IMMX Immix Biopharma, Inc. | $668.2M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| DSGN Design Therapeutics, Inc. | $653.8M | — (loss-making) | — (loss-making) | — | n/m | −37.91% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KURA Kura Oncology, Inc. | $646.7M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $641.4M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GERN Geron Corporation | $637.7M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +174.98% (above 0%: growing) | 89.95% | 9.63% | Compare |
| APMD Apnimed, Inc. | $628.6M | 0.8× | 4.3× | — | — | — | 89.98% | (96.89%) | |
| Median of peers | $661.0M | — | — | — | — | −54.33% | 44.98% | 0.00% |